［1］Bubici C，Papa S，Pham CG，et al.The NF-kappaB-mediated control of ROS and JNK signaling.Histol Histopathol，2006，21（1）：69-80.

［2］Fraley AE，Tsimikas S.Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease.Curr Opin Lipidol，2006，17（5）：502-509.

［3］Galle J，Hansen-Hagge T，Wanner C，et al.Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis，2006，185（2）：219-226.

［4］Ishigaki Y，Oka Y，Katagiri H.Circulating oxidized LDL：a biomarker and a pathogenic factor.Curr Opin Lipidol，2009，20（5）：363-369.

［5］Andersson IJ，Sankaralingam S，Davidge ST.Restraint stress up-regulates lectin-like oxidized low-density lipoprotein receptor-1 in aorta of apolipoprotein E-deficient mice.Stress，2010，13（5）：454-460.

［6］Dong K，Ge JH，Gu SL，Li S，Zhu WG，Fan FY，Zhu JH.Ox-LDL can enhance the interaction of mice natural killer cells and dendritic cells via the CD48-2B4 pathway.Heart Vessels，2011，26（6）：637-645.

［7］Jiang X，Yang Z，Chandrakala AN，Pressley D，Parthasarathy S.Oxidized low density lipoproteins-do we know enough about them？Cardiovasc Drugs Ther，2011，25（5）：367-377.

［8］Mitra S，Deshmukh A，Sachdeva R，Lu J，Mehta JL.Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy.Am J Med Sci，2011，342（2）：135-142.

［9］Mitra S，Goyal T，Mehta JL.Oxidized LDL，LOX-1 and atherosclerosis.Cardiovasc Drugs Ther，2011，25（5）：419-429.

［10］Qin B，Xiao B，Liang D，Xia J，Li Y，Yang H.MicroRNAs expression in ox-LDL treated HUVECs：MiR-365 modulates apoptosis and Bcl-2 expression.Biochem Biophys Res Commun，.2011，410（1）：127-133.

［11］Chahine MN，Dibrov E，Blackwood DP，Pierce GN.Oxidized LDL enhances stretch-induced smooth muscle cell proliferation through alterations in nuclear protein import.Can J Physiol Pharmacol，2012，90（12）：1559-1568.

［12］Itabe H.Oxidized low-density lipoprotein as a biomarker of in vivo oxidative stress：from atherosclerosis to periodontitis.J Clin Biochem Nutr，2012，51（1）：1-8.

［13］Jiang J，Yan M，Mehta JL，Hu C.Angiogenesis is a link between atherosclerosis and tumorigenesis：role of LOX-1.Cardiovasc Drugs Ther，2012，25（5）：461-468.

［14］Jiang Y，Wang M，Huang K，Zhang Z，Shao N，Zhang Y，Wang W，Wang S.Oxidized low-density lipoprotein induces secretion of interleukin-1beta by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation.Biochem Biophys Res Commun，2012，425（2）：121-126.

［15］Pirillo A，Uboldi P，Ferri N，et al.Upregulation of lectin-like oxidized low density lipoprotein receptor 1（LOX-1）expression in human endothelial cells by modified high density lipoproteins.Biochem Biophys Res Commun，2012，428（2）：230-233.

［16］Qiu J，Peng Q，Zheng Y，et al.OxLDL stimulates Id1 nucleocytoplasmic shuttling in endothelial cell angiogenesis via PI3K pathway.Biochim Biophys Acta，2012，1821（10）：1361-1369.

［17］Stellos K，Sauter R，Fahrleitner M，et al.Binding of oxidized low-density lipoprotein on circulating platelets is increased in patients with acute coronary syndromes and induces platelet adhesion to vascular wall in vivo-brief report.Arterioscler Thromb Vasc Biol，2012，32（8）：2017-2020.

［18］Stemmer U，Dunai ZA，Koller D，et al.Toxicity of oxidized phospholipids in cultured macrophages.Lipids Health Dis，2012，11：110.

［19］Tsimikas S，Miyanohara A，Hartvigsen K，et al.Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.J Am Coll Cardiol，2012，58（16）：1715-1727.

［20］Wiesner P，Choi SH，Almazan F，et al.Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1：possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia.Circ Res，2012，107（1）：56-65.

［21］Yang H，Mohamed AS，Zhou SH.Oxidized low density lipoprotein，stem cells，and atherosclerosis.Lipids Health Dis，2012，11：85.

［22］Kontush A，Chapman MJ.Functionally defective high-density lipoprotein：a new therapeutic target at the crossroads of dyslipidemia，inflammation，and atherosclerosis.Pharmacol Rev，2006，58（3）：342-374.

［23］Matsuura F，Wang N，Chen W，et al.HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway.J Clin Invest，2006，116（5）：1435-1442.

［24］Mineo C，Deguchi H，Griffin et al.Endothelial and antithrombotic actions of HDL.Circ Res，2006，98（11）：1352-1364.

［25］Tso C，Martinic G，Fan WH，et al.High-density lipoproteins enhance progenitor-mediated endothelium repair in mice.Arterioscler Thromb Vasc Biol，2006，26（5）：1144-1149.

［26］Tardif JC，Gregoire J，L’Allier PL，et al.Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis：a randomized controlled trial.JAMA，2007，297（15）：1675-1682.

［27］Murphy AJ，Woollard KJ，Hoang A，et al.High-density lipoprotein reduces the human monocyte inflammatory response.Arterioscler Thromb Vasc Biol，2008，28（11）：2071-2077.

［28］Rodriguez C，Gonzalez-Diez M，et al.Sphingosine-1-phosphate：A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin.Thromb Haemost，2009，101（4）：665-673.

［29］Nofer JR，Brodde MF，Kehrel BE.High-density lipoproteins，platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol，2010，37（7）：726-735.

［30］Toth PP.Activation of intracellular signaling systems by high-density lipoproteins.J Clin Lipido，.2010，4（5）：376-381.

［31］Cebeci E，Oner FA，Usta M，et al.Evaluation of oxidative stress，the activities of paraoxonase and arylesterase in patients with subclinic hypothyroidism.Acta Biomed，2011，82（3）：214-222.

［32］Chapman MJ，Ginsberg HN，Amarenco P，et al Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease：evidence and guidance for management.Eur Heart J，2011，32（11）：1345-1361.

［33］Redondo S，Martinez-Gonzalez J，Urraca C，et al.Emerging therapeutic strategies to enhance HDL function. Lipids Health Dis，2011，10：175.

［34］Duffy D，Holmes DN，Roe MT，et al.The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction.Am Heart J，2012，163（4）：705-713.

［35］Eren E，Yilmaz N，Aydin O.High Density Lipoprotein and it’s Dysfunction.Open Biochem J，2012，6：78-93.

［36］Landmesser U，von Eckardstein A，Kastelein J，et al.Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition：a rocky road and lessons learned？The early demise of the dal-HEART programme.Eur Heart J，2012，33（14）：1712-1715.

［37］Litvinov D，Mahini H，Garelnabi M.Antioxidant and anti-inflammatory role of paraoxonase 1：implication in arteriosclerosis diseases.N Am J Med Sci，2012，4（11）：523-532.

［38］Mackey RH，Greenland P，Goff DC，et al.High-density lipoprotein cholesterol and particle concentrations，carotid atherosclerosis，and coronary events：MESA（multi-ethnic study of atherosclerosis）.J Am Coll Cardiol，2012，60（6）：508-516.

［39］Mackness B，Mackness M.The antioxidant properties of high-density lipoproteins in atherosclerosis.Panminerva Med，2012，54（2）：83-90.

［40］Mineo C，Shaul PW.Novel biological functions of high-density lipoprotein cholesterol.Circ Res，2012，111（8）：1079-1090.

［41］Mineo C，Shaul PW.Functions of scavenger receptor class B，type Ⅰ in atherosclerosis.Curr Opin Lipidol，2012，23（5）：487-493.

［42］Rosenson RS，Brewer HB，Jr.，et al.Cholesterol efflux and atheroprotection：advancing the concept of reverse cholesterol transport.Circulation，2012，125（15）：1905-1919.

［43］Sala F，Catapano AL，Norata GD.High density lipoproteins and atherosclerosis：emerging aspects.J Geriatr Cardiol，2012，9（4）：401-407.

［44］Soran H，Hama S，Yadav R，Durrington PN.HDL functionality.Curr Opin Lipidol，2012，23（4）：353-366.

［45］Sorci-Thomas MG，Thomas MJ.High density lipoprotein biogenesis，cholesterol efflux，and immune cell function. Arterioscler Thromb Vasc Biol，2012，32（11）：2561-2565.

［46］Superko HR，Pendyala L，Williams PT，et al.High-density lipoprotein subclasses and their relationship to cardiovascular disease.J Clin Lipidol，2012，6（6）：496-523.

［47］Tall AR，Yvan-Charvet L，Westerterp M，et al.Cholesterol efflux：a novel regulator of myelopoiesis and atherogenesis.Arterioscler Thromb Vasc Biol，2012，32（11）：2547-2552.

［48］Umaerus M，Rosengren B，Fagerberg B，et al.HDL2 interferes with LDL association with arterial proteoglycans：a possible athero-protective effect.Atherosclerosis，2012，225（1）：115-120.

［49］van den Bogaard B，Holleboom AG，et al.Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness.Atherosclerosis，2012，225（2）：481-485.

［50］Wang SH，Yuan SG，Peng DQ，et al.HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells.Atherosclerosis，2012，225（1）：105-114.

［51］Botham KM，Moore EH，De Pascale C，et al.The induction of macrophage foam cell formation by chylomicron remnants.Biochem Soc Trans，2007，35（Pt 3）：454-458.

［52］Botham KM.Oxidation of chylomicron remnants and vascular dysfunction.Atherosclerosis，Suppl.2008，9（2）：57-61.

［53］Ooi EM，Barrett PH，Chan DC，Watts GF.Apolipoprotein C-Ⅲ：understanding an emerging cardiovascular risk factor.Clin Sci（Lond），2008，114（10）：611-624.

［54］De Pascale C，Graham V，Fowkes RC，et al.Suppression of nuclear factor-kappaB activity in macrophages by chylomicron remnants：modulation by the fatty acid composition of the particles.FEBS J，2009，276（19）：5689-5702.

［55］Patel S，Puranik R，Nakhla S，et al..Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins.Atherosclerosis.，2009，204（2）：424-428.

［56］Wang L，Gill R，Pedersen TL，et al.Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation.J Lipid Res，2009，50（2）：204-213.

［57］Olivecrona G，Olivecrona T.Triglyceride lipases and atherosclerosis.Curr Opin Lipidol，2010，21（5）：409-415.

［58］Chapman MJ，Ginsberg HN，Amarenco P，et al.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease：evidence and guidance for management.Eur Heart J.，2011，32（11）：1345-1361.

［59］Goldberg IJ，Eckel RH，McPherson R.Triglycerides and heart disease：still a hypothesis？Arterioscler Thromb Vasc Biol，2011，31（8）：1716-1725.

［60］Kim JY，Park JH，Jeong SW，et al.High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke.J Clin Neurol，2011，7（4）：203-209.

［61］Nakajima K，Nakano T，Tokita Y，et al.Postprandial lipoprotein metabolism：VLDL vs chylomicrons.Clin Chim Acta，2011，412（15-16）：1306-1318.

［62］Talayero BG，Sacks FM.The role of triglycerides in atherosclerosis.Curr Cardiol Rep，2011，13（6）：544-552.

［63］Bentley C，Hathaway N，Widdows J，et al.Influence of chylomicron remnants on human monocyte activation in vitro.Nutr Metab Cardiovasc Dis，2012，21（11）：871-878.

［64］den Hartigh LJ，Altman R，Hutchinson R，et al.Postprandial apoE Isoform and Conformational Changes Associated with VLDL Lipolysis Products Modulate Monocyte Inflammation.PLoS One，2012，7（11）：e50513.

［65］Kim SJ，Park YG，Kim JH，et al.Plasma fasting and nonfasting triglycerides and high-density lipoprotein cholesterol in atherosclerotic stroke：different profiles according to low-density lipoprotein cholesterol. Atherosclerosis，2012，223（2）：463-467.

［66］Tiwari S，Siddiqi SA.Intracellular trafficking and secretion of VLDL.Arterioscler Thromb Vasc Biol，2012，32（5）：1079-1086.

［67］Tomkin GH，Owens D.The chylomicron：relationship to atherosclerosis.Int J Vasc Med，2012，2012：784536.

［68］Wang J，Perrard XD，Perrard JL，et al.ApoE and the role of very low density lipoproteins in adipose tissue inflammation.Atherosclerosis，2012，223（2）：342-349.

［69］Yao Z.Human Apolipoprotein C-Ⅲ-A New Intrahepatic Protein Factor Promoting Assembly and Secretion of Very Low Density Lipoproteins.Cardiovasc Hematol Disord Drug Targets，2012，12（2）：133-140.

［70］Berg K.A New Serum Type System in Man-the Lp System.Acta Pathol Microbiol Scand，1963，59：369-382.

［71］Bennet A，Di Angelantonio E，Erqou S，et al.Lipoprotein（a）levels and risk of future coronary heart disease：large-scale prospective data.Arch Intern Med，2008，168（6）：598-608.

［72］Erqou S，Kaptoge S，Perry PL，et al.Lipoprotein（a）concentration and the risk of coronary heart disease，stroke，and nonvascular mortality.JAMA，2009，302（4）：412-423.

［73］Kamstrup PR，Tybjaerg-Hansen A，Steffensen R，et al.Genetically elevated lipoprotein（a）and increased risk of myocardial infarction.JAMA，2009，301（22）：2331-2339.

［74］Kim BS，Jung HS，Bang OY，et al.Elevated serum lipoprotein（a）as a potential predictor for combined intracranial and extracranial artery stenosis in patients with ischemic stroke.Atherosclerosis，2010，212（2）：682-688.

［75］Nordestgaard BG，Chapman MJ，Ray K，et al.Lipoprotein（a）as a cardiovascular risk factor：current status.Eur Heart J，2010，31（23）：2844-2853.

［76］Kotani K，Yamada S，Yamada T，et al.The relationship between oxidized lipoprotein（a）and carotid atherosclerosis in asymptomatic subjects：a comparison with native lipoprotein（a）.Lipids Health Dis，2011，10：174.

［77］Helgadottir A，Gretarsdottir S，Thorleifsson G，et al Apolipoprotein（a）genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.J Am Coll Cardiol，2012，60（8）：722-729.

［78］Kamstrup PR，Tybjaerg-Hansen A，Nordestgaard BG.Genetic evidence that lipoprotein（a）associates with atherosclerotic stenosis rather than venous thrombosis.Arterioscler Thromb Vasc Biol，2012，32（7）：1732-1741.

［79］Kotani K，Sakane N.Carotid Intima-Media Thickness in Asymptomatic Subjects With Low Lipoprotein（a）Levels.J Clin Med Res，2012，4（2）：130-134.

［80］Missala I，Kassner U，Steinhagen-Thiessen E.A Systematic Literature Review of the Association of Lipoprotein（a）and Autoimmune Diseases and Atherosclerosis.Int J Rheumatol，2012，2012：480784.

［81］Momiyama Y，Ohmori R，Fayad ZA，Tanaka N，Kato R，Taniguchi H，Nagata M，Ohsuzu F.Associations between serum lipoprotein（a）levels and the severity of coronary and aortic atherosclerosis.Atherosclerosis，2012，222（1）：241-244.

［82］Tsimikas S，Hall JL.Lipoprotein（a）as a potential causal genetic risk factor of cardiovascular disease：a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.J Am Coll Cardiol，2012，60（8）：716-721.

［83］Virani SS，Brautbar A，Davis BC，et al.Associations between lipoprotein（a）levels and cardiovascular outcomes in black and white subjects：the Atherosclerosis Risk in Communities（ARIC）Study.Circulation，2012，125（2）：241-249.

［84］Perk J，De Backer G，Gohlke H，et al.European Guidelines on Cardiovascular Disease Prevention in Clinical Practice（Version 2012）：the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice（constituted by representatives of nine societies and by invited experts）.Eur J Prev Cardiol，2012，19：585-667.

［85］Baigent C，Blackwell L，Emberson J，et al.Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170 000 participants in 26 randomised trials.Lancet，2010，376：1670-1681.

［86］Boekholdt SM，Arsenault BJ，Mora S，et al.Association of LDL cholesterol，non-HDL cholesterol，and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins：a meta-analysis. JAMA，2012，307（12）：1302-1309.

［87］Fukushima Y，Ohmura H，Mokuno H，et al.Non-high-density lipoprotein cholesterol is a practical predictor of long-term cardiac death after coronary artery bypass grafting.Atherosclerosis，2012，221（1）：206-211.

［88］Rana JS，Boekholdt SM，Kastelein JJ，et al.The role of non-HDL cholesterol in risk stratification for coronary artery disease.Curr Atheroscler Rep，2012，14（2）：130-134.

［89］Blaha MJ，Nasir K，Blumenthal RS.Statin Therapy for Healthy Men Identified as “Increased Risk”.JAMA，2012，307（14）：1489-1490.

［90］Redberg RF，Katz MH.Healthy Men Should Not Take Statins.Author Affiliations：Division of Cardiology，Department of Medicine，University of California，San Francisco（Dr Redberg），and Department of Health Services，County of Los Angeles，Los Angeles，California（Dr Katz）.Dr Redberg is also Editor， Archives ofInternal Medicine.Dr Katz is also Deputy Editor， Archives of Internal Medicine.JAMA，2012，307（14）：1491-1492.

［91］Mulders TA，Sivapalaratnam S，Stroes ES，et al.Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment：a post hoc analysis from the St.Francis Heart Study.JACC Cardiovasc Imaging，2012，5（3）：252-260.

［92］Kohli P，Cannon CP.Triglycerides：how much credit do they deserve？Med Clin North Am，2012，96（1）：39-55.

［93］Atar IA，Atar I，Aydinalp A，et al.Is there any relationship between coronary artery disease and postprandial triglyceride levels？Anadolu Kardiyol Derg，2011，11（3）：201-206.

［94］European Association for Cardiovascular Prevention ＆ Rehabilitation，ESC Committee for Practice Guidelines（CPG）2008-2010 and 2010-2012 Committees.ESC/EAS Guidelines for the management of dyslipidaemias：the Task Force for the management of dyslipidaemias of the European Society of Cardiology（ESC）and the European Atherosclerosis Society（EAS）.Eur Heart J，2011，32（14）：1769-818.

［95］Jun M，Foote C，Lv J，et al.Effects of fibrates on cardiovascular outcomes：a systematic review and meta-analysis The Lancet，2010，375：1875-1884.

［96］陆宗良，顼志敏.血脂异常的治疗.北京：人民卫生出版社，2008.

［97］Nichols GA，Vupputuri S，Rosales AG.Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus.Am J Cardiol，2011，108（8）：1124-1128.

［98］Costacou T，Evans RW，Orchard TJ.High-density lipoprotein cholesterol in diabetes：is higher always better？J Clin Lipidol，2011，5（5）：387-394.

［99］Oravec S，Dostal E，Dukit A，et al.HDL subfractions analysis：a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.Neuro Endocrinol Lett，.2011，32（4）：502-509.

［100］Orakzai SH，Nasir K，Blaha M，et al.non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals.Atherosclerosis，2009，202（1）：289-295.

［101］Ballantyne CM，Raichlen JS，Cain VA.Statin therapy alters the relationship between apolipoprotein B and lowdensity lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients：the MERCURY Ⅱ（Measuring Effective Reductions in Cholesterol Using Rosuvastatin）trial.J Am Coll Cardiol，2008，52（8）：626-632.

［102］Malave H，Castro M，Burkle J，et al.Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50mg/dl and non-high-density lipoprotein cholesterol <80mg/dl.Am J Cardiol，2012，110（5）：662-5.

［103］Parish S，Offer A，Clarke R，et al.，Heart Protection Study Collaborative Group.Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.Circulation，2012，125（20）：2469-2478.

［104］Duffy D，Holmes DN，Roe MT，et al..The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction.Am Heart J，2012，163（4）：705-713.

［105］Balogh E，Bereczky Z，Katona E，et al.Interaction between homocysteine and lipoprotein（a）increases the prevalence of coronary artery disease/myocardial infarction in women：a case-control study.Thromb Res，2012，129（2）：133-138.

［106］Taylor F，Ward K，Moore TH，et al.Statins for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev，2011，19，（1）：CD004816.

［107］Lunegova OS，Pavlenko MA，Kerimkulova AS，et al.Association of the serum level of apolipoprotein E with coronary artery disease and carotid artery atherosclerosis in Kyrgyz men with dyslipidemia.Ter Arkh，2010，82（9）：18-23.

［108］中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南.北京：人民卫生出版社，2007.

［109］Robinson JG，Wang S，Smith BJ，Jacobson TA.Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.J Am Coll Cardiol，2009，53（4）：316-322.

［110］Armitage J，Bowman L，Wallendszus K，et al.Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12 064 survivors of myocardial infarction：a double-blind randomised trial.Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine（SEARCH）Collaborative Group，Lancet，2010，376（9753）：1658-1669.

［111］Nissen SE，Tuzcu EM，Schoenhagen P，et al.Reversal of Atherosclerosis with Aggressive Lipid Lowering（REVERSAL）Investigators.Statin therapy，LDL cholesterol，C-reactive protein，and coronary artery disease.N Engl J Med，2005，352（1）：29-38.

［112］Kjekshus J，Apetrei E，Barrios V，et al.Rosuvastatin in older patients with systolic heart failure.N Engl J Med，2007，357（22）：2248-2261.

［113］Tavazzi L，Maggioni AP，Marchioli R，et al.Effect of rosuvastatin in patients with chronic heart failure（the GISSI-HF trial）：a randomised，double-blind，placebo-controlled trial.Lancet，2008，372（9645）：1231-1239.

［114］Schouten O，Boersma E，Hoeks SE，et al.Fluvastatin and perioperative events in patients undergoing vascular surgery.N Engl J Med，2009，361（10）：980-989.

［115］Tleyjeh IM，Kashour T，Hakim FA，et al.Statins for the prevention and treatment of infections：a systematic review and meta-analysis.Arch Intern Med，2009，169（18）：1658-1667.

［116］Birnbaum Y，Ye Y，Farmer J.Modulation of eicosanoid production and activity as a potential explanation for some of the pleiotropic effects of statins.Cardiology，2010，116（1）：45-47.

［117］Chuengsamarn S，Rattanamongkoulgul S，Suwanwalaikorn S，et al.Effects of statins vs.non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.Bone，2010，46（4）：1011-1015.

［118］Klawitter J，Shokati T，Moll V，et al .Effects of lovastatin on breast cancer cells：a proteo-metabonomic study. Breast Cancer Res，2010，12（2）：R16.

［119］Mihos CG，Salas MJ，Santana O.The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease：a comprehensive review.Cardiol Rev，2010，18（6）：298-304.

［120］Nilsson L，Eriksson P，Cherfan P，et al.Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals.Inflammation，2010，34（4）：225-230.

［121］Pedersen TR.Pleiotropic effects of statins：evidence against benefits beyond LDL-cholesterol lowering.Am J Cardiovasc Drugs，2010，10 Suppl 1：10-17.

［122］Ali OF，Growcott EJ，Butrous GS，et al.Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells.Respir Res，2011，12：137.

［123］Balakumar P，Kathuria S，Taneja G，et al.Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins？J Mol Cell Cardiol，2011，52（1）：83-92.

［124］Douglas I，Evans S，Smeeth L.Effect of statin treatment on short term mortality after pneumonia episode：cohort study.BMJ，2011，342：d1642.

［125］Kouroumichakis I，Papanas N，Proikaki S，Zarogoulidis P，Maltezos E.Statins in prevention and treatment of severe sepsis and septic shock.Eur J Intern Med，2011，22（2）：125-133.

［126］Rutishauser J.Statins in clinical medicine.Swiss Med Wkly.，2011，141：w13310.

［127］Yamamoto C，Fukuda N，Jumabay M，et al.Protective effects of statin on cardiac fibrosis and apoptosis in adrenomedullin-knockout mice treated with angiotensin Ⅱ and high salt loading.Hypertens Res，2011，34（3）：348-353.

［128］Brioschi M，Lento S，Tremoli E，et al.Proteomic analysis of endothelial cell secretome：A means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors.J Proteomics，2012，78：346-361.

［129］Grigore L，Raselli S，Garlaschelli Ket al.Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia.Eur J Clin，Pharmacol.2012.

［130］Kameda Y，Hasegawa H，Kubota A，et al.Effects of pitavastatin on pressure overload-induced heart failure in mice.Circ J，2012，76（5）：1159-1168.

［131］Kwok JM，Ma CC，Ma S.Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase.Vascul Pharmacol，2012，58（1-2）：21-30.

［132］Marasini B，Massarotti M.Statins and cardiovascular risk in rheumatic diseases.Int J Immunopathol Pharmacol，2012，25（1）：25-30.

［133］Salem NA，Assaf N，Ahmed HH.Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats.Eur Rev Med Pharmacol Sci，2012，16（6）：797-807.

［134］Spindler SR，Li R，Dhahbi JM，Yamakawa A，Mote P，Bodmer R，Ocorr K，Williams RT，Wang Y，Ablao KP. Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation.PLoS One，2012，7（6）：e39581.

［135］Stach K，Nguyen XD，Lang S，et al.Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand.Cardiol J，2012，19（1）：20-28.

［136］Tasat DR，Yakisich JS.Expanding the pleiotropic effects of statins：attenuation of air pollution-induced inflammatory response.Am J Physiol Lung Cell Mol Physiol，2012，303（8）：L640-641.

［137］Wustmann K，Klaey M，Burow A，et al.Additive effect of homocysteine-and cholesterol-lowering therapy on endothelium-dependent vasodilation in patients with cardiovascular disease.Cardiovasc Ther，2012，30（5）：277-286.

［138］Keech A，Simes RJ，Barter P，et al.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus（the FIELD study）：randomised controlled trial.Lancet，2005，366：1849-1861.

［139］Tenenbaum A，Motro M，Fisman EZ，et al.Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.Arch Intern Med，2005，165：1154-1160.

［140］Liao D，Tan H，Hui R，et al.Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance.Circ Res，2006，99：598-606.

［141］Mikael LG，Genest J Jr，Rozen R.Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease.Circ Res，2006，98：564-571.

［142］Kamanna VS，Ganji SH，Kashyap ML.Niacin：an old drug rejuvenated.Curr Atheroscler Rep，2009，11：45-51.

［143］Paul L.C，Curt D.Furberg，et al.Benefits of Niacin by Glycemic Status in Patients With Healed Myocardial Infarction（from the Coronary Drug Project）.Am J Cardiol，2005，95：254-257.

［144］Allen J.T，H yun J.L，Lance E.S，et al.The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness：ARBITER 3*.Current Medical R esearch a nd Opinion，2006，22：2243-2250.

［145］Todd C.V，Eric J.S，Patrick J.D，et al.The ARBITER 6-HALTS Trial（Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis）Final Results and the Impact of Medication Adherence，Dose，and Treatment Duration.J Am Coll Cardiol，2010，55：2721-2726.

［146］Ballantyne CM，Davidson MH，McKenney J，et al.Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non-HDL Cholesterol（from the SEACOAST I Study）.Am J Cardiol，2008，101：1428-1436.

［147］Ballantyne CM，Davidson MH，McKenney J，et al.Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy：the SEACOAST Ⅱ（high-dose）study.Journal of Clinical Lipidology，2008，2：79-90.

［148］AIM-HIGH Investigators，Boden WE，Probstfield JL，Anderson T，et al.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med，2011，365（24）：2255-67.

［149］Gissi-Hf I .Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure（the GISSI-HF trial）：a randomised，double-blind，placebo-controlled trial.Lancet，2008，372：1223-1230.

［150］Yokoyama M，Origasa H，Matsuzaki M，et al.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS）：a randomized open-label，blinded endpoint analysis.Lancet，2007，369：1090-1098.

［151］Mozaffarian D.JELIS，fish oil，and cardiac events.Lancet，2007，369：1062-1063.

［152］Mozaffarian D.Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death.Am J Clin Nutr，2008，87：1991S-1996S.

［153］Hooper L，Thompson RL，Harrison RA，et al..Risks and benefits of omega 3 fats for mortality，cardiovascular disease，and cancer：systematic review.BMJ，2006，332：752-760.

［154］Wang C，Harris WS，Chung M，et al..n-3 Fatty acids from fish or fish-oil supplements，but not alpha-linolenic acid，benefit cardiovascular disease outcomes in primary-and secondary-prevention studies：a systematic review. Am J Clin Nutr，2006，84：5-17.

［155］Phan BA，Dayspring TD，Toth PP.Ezetimibe therapy：mechanism of action and clinical update.Vascular Health and Risk Management，2012，8：415-427.

［156］Rossebø AB，Pedersen TR，Boman K，et al.Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis.N Engl J Med 2008，359：1343-1356.

［157］Baigent C，Landray MJ，Reith C，et al.The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease（Study of Heart and Renal Protection）：a randomized placebo-controlled trial.Lancet，2011，377（9784）：2181-2192.

［158］Stein EA，Mellis S，Yancopoulos GD，et al.Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol.N Engl J Med 2012，366：1108-18.

［159］McKenney JM，Koren MJ，Kereiakes DJ，et al.Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease，SAR236553/REGN727，in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy.J Am Coll Cardiol，2012，59：2344-53.

［160］Stein EA，Gipe D，Bergeron J，et al.Effect of a monoclonal antibody to PCSK9，REGN727/SAR236553，to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy：a phase 2 randomised controlled trial.Lancet，2012，380：29-36.

［161］Stein EA，Dufour R，Gagne C，et al.Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia Results of a Randomized，Double-Blind，Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease.Circulation，2012，126：2283-2292.

［162］Akdim F，Visser ME，Tribble DL，et al.Effect of Mipomersen，an Apolipoprotein B Synthesis Inhibitor，on Low-Density Lipoprotein Cholesterol in Patients With Familial HypercholesterolemiaAm J Cardiol，2010，105：1413-1419.

［163］Kim E，Campbell S，Schueller O，et al.A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein，SLx-4090：Biochemical，Pharmacodynamic，Pharmacokinetic，and Safety Profile.THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS，2011，337：775-785.

［164］Cuchel M，Meagher EA，du Toit Theron H，et al.Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia：a single-arm，open-label，phase 3 study. Lancet，2013，381（9860）：40-46.

［165］Barter PJ，Caulfield M，Eriksson M，et al.Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med，2007，，357（21）：2109-22.

［166］Gregory G.S，Anders G.O，Markus A，et al.for the dal-OUTCOMES Investigators.Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome.N Engl J Med，2012，367：2089-2099.

［167］S Redondo，J Martínez-González3，C Urraca，et al..Emerging therapeutic strategies to enhance HDL function. Lipids in Health and Disease，2011，10：175-182.

［168］M Navab，ST.Reddy，BJ.V Lenten，et al.HDL and cardiovascular disease：atherogenic and atheroprotective mechanisms.Nat.Rev.Cardiol，2011，8，222-232.

［169］Chenevard R，Hürlimann D，Spieker L，Béchir M，et al.Reconstituted HDL in acute coronary syndromes.，2012，30（2）：e51-57.

［170］Robinson JG，Davidson MH.Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.Expert Rev.Cardiovasc.2006，Ther.4（4），461-476.

［171］Ijioma N，Robinson JG.Lipid-lowering effects of ezetimibe and simvastatin in combination.Expert Rev Cardiovasc Ther，2011，9（2）：131-145.

［172］Ballantyne CM，Davidson MH，McKenney J，et al.Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol（from the SEACOAST I Study）.Am J Cardiol，2008，101：1428-1436.

［173］Taylor A，Lee H，Sullenberger L.The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness：ARBITER 3.Curr Opin Med Res Opin，2006，22：2243-2250.

［174］Allen JT，Todd CV，Erie JS，et a1.Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness. N EngI J Med，2009，361：2113-2122.

［175］Vo AN，Kashyap ML.Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Rev Cardiovasc Ther，2008，6（10）：1303-10.

［176］Robinson JG.Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.Vasc Health Risk Manag.，2009，5（1）：31-43.

［177］Karas RH，Kashyap ML，Knopp RH，Keller LH，Bajorunas DR，Davidson MH.Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia：The OCEANS study. Am J Cardiovasc Drugs，2008，8：69-81.

［178］Guyton JR，Bays HE.Safety considerations with niacin therapy.Am J Cardiol，2007，99（6 Suppl 1）：S22-S31.

［179］Ballantyne C，Davidson MH，McKenney JM，Keller LH，Bajorunas DR，Karas RH.Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvstatin 80 mg montherapy：the SEACOAST Ⅱ（high dose）study.J Clin Lipidol，2008，2：79-90.

［180］Ginsberg HN，Elam MB，Lovato LC，et al.Effects of combination lipid therapy in type 2 diabetes mellitus.N Engl J Med，2010，362：1563-1574.

［181］Neuvonen PJ，Niemi M，Backman JT.Drug interactions with lipid-lowering drugs：Mechanisms and clinical relevance.Clin Pharmacol Ther，2006，80：565-581.

［182］Elam M，Lovato LC and Ginsberg H.Role of fibrates in cardiovascular disease prevention，the ACCORD-Lipid perspective.Current Opinion in Lipidology，2011，22：55-61.

［183］DG.Johns，J Duffy，T Fisher，BK.Hubbard and Michael J.On-and Off-Target Pharmacology of Torcetrapib：Current Understanding and Implications for the Structure Activity Relationships（SAR），Discovery and Development of Cholesteryl Ester-Transfer Protein（CETP）Inhibitors.Drugs，2012，72（4）：491-507.

［184］Armitage，J.The safety of statins in clinical practice.Lancet，2007，370（9601）：1781-1790.

［185］Beltowski，J.，Wojcicka，G.，Jamroz-Wisniewska，A.Adverse effects of statins-mechanisms and consequences. Curr Drug Saf，2009，4：209-228.

［186］Brown，W.V.Safety of statins.Curr Opin Lipidol，2008，19：558-562.

［187］Sattar，N.，Preiss，D.，Murray，H.M.，et al.Statins and risk of incident diabetes：a collaborative meta-analysis of randomised statin trials.Lancet，2010 375：735-742.

［188］Bays，H.Statin safety：an overview and assessment of the data-2005.Am J Cardiol，2006，97：6C-26C.

［189］Link，E.，Parish，S.，Armitage，J.，et al.SLCO1B1 variants and statininduced myopathy-a genomewide study.N Engl J Med，2008，359（8）：789-799.

［190］Peters，B.J.，Klungel，O.H.，Visseren，F.L.，et al.Pharmacogenomic insights into treatment and management of statin-induced myopathy.Genome Med，2009，1：120.

［191］Backes，J.M.，Howard，P.A.，Ruisinger，J.F.，et al.Does simvastatin cause more myotoxicity compared with other statins？Ann Pharmacother，2009，43：2012-2020.

［192］Fung，E.C.，Crook，M.A..Statin myopathy：a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther，2011，30（5）：e212-218.

［193］Corsini，A.，Ceska，R.Drug-drug interactions with statins：will pitavastatin overcome the statins’ Achilles’heel？Curr Med Res Opin，2011，27：1551-1562.

［194］Abd，T.T.，Jacobson，T.A.Statin-induced myopathy：a review and update.Expert Opin Drug Saf，2011，10：373-387.

［195］Gillett RC Jr，Norrell A.Considerations for safe use of statins：liver enzyme abnormalities and muscle toxicitiy. Am Fam Physician，2011，83：711-716.

［196］Thompson，P.D.，Clarkson，P.M.，Rosenson，R.S.An assessment of statin safety by muscle experts.Am J Cardiol，2006，97：69C-76C.

［197］Armitage，J.，Bowman，L.，Wallendszus，K.，et al.Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction：a double-blind randomised trial.Lancet，2010，376：1658-1669.

［198］Newman，C.，Tsai，J.，Szarek，M.，et al.Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14，236 patients.Am J Cardiol，2006，97：61-67.

［199］Wolfe，S.M.Dangers of rosuvastatin identified before and after FDA approval.Lancet，2004，363：2189-2190.

［200］Shepherd，J.，Vidt，D.G.，Miller，E.，et al.Safety of rosuvastatin：update on 16，876 rosuvastatin-treated patients in a multinational clinical trial program.Cardiology，2007，107：433-443.

［201］Toth，P.P.，Dayspring，T.D.Drug safety evaluation of rosuvastatin.Expert Opin Drug Saf，2011，10：969-986.

［202］Alsheikh-Ali，A.A.，Karas，R.H.Safety of lovastatin/extended release niacin compared with lovastatin alone，atorvastatin alone，pravastatin alone，and simvastatin alone（from the United States Food and Drug Administration adverse event reporting system）.Am J Cardiol，2007，99：379-381.

［203］da Silva，P.M.Are all statins the same？Focus on the efficacy and tolerability of pitavastatin.Am J Cardiovasc Drugs，2011，11：93-107.

［204］del Sol，A.I.，Nanayakkara，P.W.Pravastatin：an evidence-based statin？Expert Opin Drug Metab Toxicol，2008，4：821-825.

［205］Chatzizisis，Y.S.，Koskinas，K.C.，Misirli，G.，et al.Risk factors and drug interactions predisposing to statininduced myopathy：implications for risk assessment，prevention and treatment.Drug Saf，2010，33：171-187.

［206］Kashani，A.，Phillips，C.O.，Foody，J.M.，et al.Risks associated with statin therapy：a systematic overview of randomized clinical trials.Circulation，2006，114：2788-2797.

［207］Bottorff，M.B.Statin safety and drug interactions：clinical implications.Am J Cardiol，2006，97：27C-31C.

［208］Frishman，W.H.，Horn，J.Statin-drug interactions：not a class effect.Cardiol Rev，2008，16：205-212.

［209］Neuvonen，P.J.，Niemi，M.，Backman，J.T.Drug interactions with lipid-lowering drugs：mechanisms and clinical relevance.Clin Pharmacol Ther，2006，80：565-581.

［210］Holtzman，C.W.，Wiggins，B.S.，Spinler，S.A..Role of P-glycoprotein in statin drug interactions. Pharmacotherapy，2006，26：1601-1607.

［211］Ieiri，I.，Higuchi，S.，Sugiyama，Y..Genetic polymorphisms of uptake（OATP1B1，1B3）and efflux（MRP2，BCRP）transporters：implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Expert Opin Drug Metab Toxicol，2009，5：703-729.

［212］Joy，T.R.，Hegele，R.A..Narrative review：statin-related myopathy.Ann Intern Med，2009，150：858-868.

［213］Macoff，L.，Thompson，P.D.The role of coenzyme Q10 in statin-associated myopathy：a systematic review.J Am Coll Cardiol，2007，49：2231-2237.

［214］Oh，J.，Ban，M.R.，Miskie，B.A.，et al.Genetic determinants of statin intolerance.Lipids Health Dis，2007，6：7.

［215］Young，J.M.，Florkowski，C.M.，Molyneux，S.L.，et al.Effect of coenzyme Q（10）supplementation on simvastatininduced myalgia.Am J Cardiol，2007，100：1400-1403.

［216］Erkal，M.Z.，Wilde，J.，Bilgin，Y.，et al.High prevalence of vitamin D deficiency，secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany：identification of risk factors.Osteoporos Int，2006，17：1133-1140.

［217］Bunout，D.，Barrera，G.，Leiva，L.，et al.Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects.Exp Gerontol，2006，41：746-752.

［218］Ahmed，W.，Khan，N.，Glueck，C.J.，et al.Low serum 25（OH）vitamin D levels（<32ng/mL）are associated with reversible myositis-myalgia in statin-treated patients.Transl Res，2009，153：11-16.

［219］Glueck，C.J.，Abuchaibe，C.，Wang，P..Symptomatic myositis-myalgia in hypercholesterolemic statintreated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle.Med Hypotheses，2011，77：658-661.

［220］Lee，P.，Greenfield，J.R.，Campbell，L.V..Vitamin D insufficiency-a novel mechanism of statin-induced myalgia？Clin Endocrinol（Oxf），2009，71：154-155.

［221］Pérez-Castrillón JL，Vega G，Abad L，et al.Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease.Am J Cardiol，2009，99：903-905.

［222］Yavuz，B.，Ertugrul，D.T.，Cil，H.，et al.Increasedlevels of 25 hydroxyvitamin D and 1，25-dihydroxyvitamin D after rosuvastatintreatment：a novel pleiotropic effect of statins？Cardiovasc Drugs Ther，2009，23：295-299.

［223］Rejnmark，L.，Vestergaard，P.，Heickendorff，L.et al.Simvastatin does not affect vitamin d status，but low vitamin d levels are associated with dyslipidemia：results from a randomised，controlled trial.Int J Endocrinol， 2010：957174.

［224］Argo C.K.，Loria P.，Caldwell S.H.，et al.Statins in liver disease：a molehill，an iceberg，or neither？Hepatology，2008，48：662-669.

［225］McKenney J.M.，Davidson M.H.，Jacobson T.A.，et al.Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.Am J Cardiol，2006，97：89C-94C.

［226］Musso G.，Cassader，M.，Gambino，R..Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease：an update.Curr Opin Lipidol，2011，22：489-496.

［227］Tandra S.，Vuppalanchi R.Use of statins in patients with liver disease.Curr Treat Options Cardiovasc Med 11：272-278.

［228］Zamor，P.J.，Russo，M.W..Liver function tests and statins.Curr Opin Cardiol，2011，26：338-341.

［229］Athyros，V.G.，Tziomalos，K.，Gossios，T.D.，et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation（GREACE）Study：a post-hoc analysis.Lancet，2011，376：1916-1922.

［230］Lewis，J.H.，Mortensen，M.E.，Zweig，S.，et al.Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease：Results of a prospective，randomized，double-blind，placebo-controlled，multicenter trial.Hepatology，2009，46：1453-1463.

［231］Ridker，P.M.，Danielson，E.，Fonseca，F.A.，et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med，2008，359：2195-2207.

［232］Sampson，U.K.，Linton，M.F.，Fazio，S..Are statins diabetogenic？Curr Opin Cardiol，2011，26：342-347.

［233］Preiss，D.，Seshasai，S.R.，Welsh，P.，et al.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy：a meta-analysis.JAMA，2011，305：2556-2564.

［234］Bhatia，L.，Byrne，C.D..There is a slight increase in incident diabetes risk with the use of statins，but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk.Evid Based Med，2010，15：84-85.

［235］Elliott，W.J.，Meyer，P.M..Incident diabetes in clinical trials of antihypertensive drugs：a network meta-analysis. Lancet，2007，369：201-207.

［236］Kearney，P.M.，Blackwell，L.，Collins，R.，et al.Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins：a meta-analysis.Lancet，2008，371（9607）：117-125.

［237］Preiss，D.，Sattar，N..Statins and the risk of new-onset diabetes：a review of recent evidence.Curr Opin Lipidol，2011，22：460-466.

［238］Athyros，V.G.，Tziomalos，K.，Karagiannis，A.，et al.Aggressive statin treatment，very low serum cholesterol levels and haemorrhagic stroke：is there an association？Curr Opin Cardiol，2010，25：406-410.

［239］Bersano，A.，Ballabio，E.，Lanfranconi，S.，et al.Statins and stroke.Curr Med Chem，2008，15：2380-2392.

［240］Rodriguez-Yanez，M.，Agulla，J.，Rodriguez-Gonzalez，R.，et al.Statins and stroke.Ther Adv Cardiovasc Dis，2008，2：157-166.

［241］De Caterina，R.，Scarano，M.，Marfisi，R.，et al.Cholesterol-lowering interventions and stroke：insights from a meta-analysis of randomized controlled trials.J Am Coll Cardiol，2010，55：198-211.

［242］Noda，H.，Iso，H.，Irie，F.，et al.Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage：the Ibaraki Prefectural Health Study.Circulation，2009，119：2136-2145.

［243］Zhao，D.，Liu，J.，Wang，W.，et al.Epidemiological transition of stroke in China：twenty-one-year observational study from the Sino-MONICA-Beijing Project.Stroke，2008，39：1668-1674.

［244］Amarenco，P.，Bogousslavsky，J.，Callahan，A.，et al.，High-dose atorvastatin after stroke or transient ischemic attack.N Engl J Med，2006，355：549-559.

［245］Goldstein，L.B.，Amarenco，P.，Szarek，M.，et al.Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.Neurology，2008，70：2364-2370.

［246］Hackam，D.G.，Austin，P.C.，Huang，A.，et al.Statins and intracerebral hemorrhage：a retrospective cohort study.Arch Neurol，2012，69：39-45.

［247］Hackam，D.G.，Woodward，M.，Newby，L.K.，et al.Statins and intracerebral hemorrhage：collaborative systematic review and meta-analysis.Circulation，2011，124：2233-2242.

［248］Amarenco，P.，Labreuche，J..Lipid management in the prevention of stroke：review and updated meta-analysis of statins for stroke prevention.Lancet Neurol，2009，8：453-463.

［249］Everett，B.M.，Glynn，R.J.，MacFadyen，J.G.，et al.Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein：justification for the Use of Statins in Prevention：an Intervention Trial Evaluating Rosuvastatin（JUPITER）.Circulation，2010，121：143-150.

［250］Baigent，C.，Blackwell，L.，Emberson，J.，et al.Efficacy and safety of more intensive lowering of LDL cholesterol：a meta-analysis of data from 170 000 participants in 26 randomised trials.Lancet，2010，376：1670-1681.

［251］Josan，K.，Majumdar，S.R.，McAlister，F.A..The efficacy and safety of intensive statin therapy：a meta-analysis of randomized trials.CMAJ，2008，178：576-584.